Abstract

Background

The epidemiological data have linked atrial fibrillation (AF) risk with hypertension.

The surging wearable devices allow noninvasive beat-by-beat blood pressure monitoring.

Objective

The present study aimed to investigate dynamic changes on blood pressure with wearable blood pressure monitors and its-related risk for AF occurrence.

Methods

In the mobile Atrial Fibrillation Application (mAFA II) programme, the subjects used the photoplethysmography (PPG)-based smart devices to detect the AF episodes. They simultaneously freely decided whether to take the wearables to monitor their blood pressure.

Results

There were 25388 subjects (mean age ± standard deviation, SD, 48±12 years old, 90.4% male) who received simultaneously blood pressure and cardiac rhythm monitoring with the wearables between Jan 1, 2022 and March 19, 2022. The monitored time (median, interquartile) were 6 (12–18) days and the number of measurements of blood pressure were 16 (3–56).

The 8830 subjects (34.8%, 8830/25388) monitored with average 24-hour BP >130/80 mm Hg and 945 subjects (10%, 945/8830) with pulse differential over 60 mmHg.

The extreme-dippers blood pressure and reverse-dippers blood pressure were in 8563 subjects (33.7%, 8563/25388) and 7018 subjects (27.6%, 7018/25388), respectively.

There were 498 subjects (58±12 years, 89% male) who identified with AF. After adjusting age, gender, diabetes, obstructive sleep apnea, heart failure, coronary artery disease, and hyperthyroidism, the average 24-hour BP >130/80 mm Hg (Odd ratio, OR, 95% confidential interval, CI, 1.38, 1.12–1.69, p=0.002), the reverse-dippers blood pressure (OR, 95% CI, 1.29, 1.07–1.56, p=0.008) and pulse differential over 60 mmHg (OR, 95% CI, 1.76,1.17–2.64, p=0.006) independently predicted the risk of AF.

Conclusion

Wearable devices with beat-by-beat monitoring demonstrated that not only high average 24-hour BP, but also reverse-dippers blood pressure and pulse differential over 60 mmHg increased AF susceptibility, which informing the clinical application of personalized “upstream risk control” of AF.

Funding Acknowledgement

Type of funding sources: Public grant(s) – National budget only. Main funding source(s): National Natural Science Foundation of China

This content is only available as a PDF.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [email protected]